Olatec Therapeutics Adds Parkinson’s Disease Experts
New York, New York, U.S., September 15, 2026 Olatec Therapeutics, Inc., a clinical-stage biotechnology company developing therapies for inflammatory...
Cancer Treatment
Advertisement
Astellas PADCEV and Keytruda Gain Positive CHMP Opinion
Tokyo, Japan, September 17, 2026 Astellas Pharma Inc. has announced that the European Medicines Agency’s Committee for Medicinal Products...
Akeso AK158D1 Gets NMPA Phase I Clearance for Tumors
Hong Kong, September 17, 2026 Akeso, Inc. has announced that its investigational AK158D1, a next-generation EGFR/TROP2 bispecific antibody-drug conjugate...
Roche Lunsumio Regimen Improves PFS in Follicular Lymphoma
Basel, Switzerland, September 17, 2026 Roche has announced positive results from the Phase III CELESTIMO study, showing that a...
Fennec Pharmaceuticals Presents Two-Year Pedmark Data in Japan
RESEARCH TRIANGLE PARK, N.C. — September 17, 2026 Fennec Pharmaceuticals announced the oral presentation of detailed results from the...
Advertisements
Biofrontera Gains FDA Approval for Ameluz in Basal Cell Carcinoma
WOBURN, Mass. — September 14, 2026 Biofrontera Inc. announced that the U.S. Food and Drug Administration (FDA) has approved...
Ocumension Therapeutics Advances OT-301 in China
Hong Kong, China, September 11, 2026 Ocumension Therapeutics has announced that the National Medical Products Administration (NMPA) of China...
CU Anschutz Wins FDA Clearance for CAR T Cancer Trial
Aurora, Colorado, U.S., September 10, 2026 University of Colorado Anschutz Medical Campus (CU Anschutz) has received U.S. Food and...
Johnson & Johnson Gains CE Mark for ACUVUE OASYS MAX
Limerick, Ireland, September 10, 2026 Johnson & Johnson has announced that it has received CE Marking for ACUVUE OASYS...
Marengo Completes STARt-001 Enrollment, Strengthens Team
Cambridge, Massachusetts, September 9, 2026 Marengo Therapeutics has completed enrollment in the monotherapy cohorts of its Phase 1/2 STARt-001...
Advertisement
